Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NU6102 是一种具有选择性和有效性的 ATP 竞争性 CDK2 抑制剂,具有抗肿瘤活性,对 CDK1/cyclinB、CDK2/cyclinA3、CDK1/CDK2、 CDK4、DYRK1A 、PDK1、ROCKII 具有抑制作用,可用于研究直肠癌。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 489 | 现货 | ||
5 mg | ¥ 1,180 | 现货 | ||
10 mg | ¥ 1,880 | 现货 | ||
25 mg | ¥ 3,790 | 现货 | ||
50 mg | ¥ 6,130 | 现货 | ||
100 mg | ¥ 8,270 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,320 | 现货 |
产品描述 | NU6102 is a selective and potent ATP-competitive CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK2/cyclinA3, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer. |
靶点活性 | PDK1:0.8 μM, DYRK1A:0.9 μM, CDK4:1.6 μM, CDK2-CyclinA3:5.4 nM, CDK1-CyclinB:9.5 nM |
体外活性 | Treatment with NU6102 (0-30 μM; 1-24 hours) induces G2 arrest, inhibition of Rb phosphorylation, and cytotoxicity (LC50 2.6 μM for a 24-hour exposure) in SKUT-1B cells[3]. NU6102 inhibits cell growth and causes cell cycle phase arrest in human breast cancer cell lines, displaying G2/M arrest in asynchronously growing cell lines and G1/S arrest in cells released from serum starvation, and in Xenopus nuclei in a time-dependent manner[3]. Moreover, NU6102 selectively inhibits the growth of CDK2 WT (wild type) compared to KO MEFs (knockout mouse embryo fibroblasts) with a GI50 of 14 μM versus >30 μM[3]. |
体内活性 | The pharmacokinetics of NU6102 are determined in Balb/C mice following i.v. and i.p. administration. Due to the limited solubility of NU6102, the maximum administrable dose is 1 mg/kg i.v. and 10 mg/kg i.p. NU6102 is liberated following either i.p. or i.v. administration of NU6301. After i.v. administration, peak plasma levels of 12 μM NU6102 are observed 5 minutes post-administration, while the peak concentration achieved with the maximum administrable dose of NU6102 i.v. is 0.92 μM. The plasma half-life of NU6102 liberated following NU6301 administration is 42 minutes after i.p. and 10 minutes after i.v. administration[3]. |
别名 | NU-6102, NU 6102 |
分子量 | 402.47 |
分子式 | C18H22N6O3S |
CAS No. | 444722-95-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL(198.77 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4847 mL | 12.4233 mL | 24.8466 mL | 62.1164 mL |
5 mM | 0.4969 mL | 2.4847 mL | 4.9693 mL | 12.4233 mL | |
10 mM | 0.2485 mL | 1.2423 mL | 2.4847 mL | 6.2116 mL | |
20 mM | 0.1242 mL | 0.6212 mL | 1.2423 mL | 3.1058 mL | |
50 mM | 0.0497 mL | 0.2485 mL | 0.4969 mL | 1.2423 mL | |
100 mM | 0.0248 mL | 0.1242 mL | 0.2485 mL | 0.6212 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NU6102 444722-95-6 Cell Cycle/Checkpoint CDK NU-6102 NU 6102 Inhibitor inhibitor inhibit